A new article published in Experimental Hematology & Oncology by Mayo clinic (USA), Karolinska institutet, and Oxcia AB, shows that OXC-101, a mitotic MTH1 inhibitor, kills ovarian cancer independent of platinum sensitivity.
The standard of care therapy for ovarian cancer consists of platinum drugs, e.g. carboplatin. However, the majority of ovarian cancer patients eventually develops resistance to platinum drugs, which is associated with a one-year median survival as current treatments do not work satisfactorily at this stage. Thus, the need for new therapies is high. A therapy that kills ovarian cancer cells regardless of platinum sensitivity would be a big step forward.
In a collaboration with Karolinska Institute, Sweden and one of the prominent oncology institutions in US, the Mayo clinic, Oxcia has explored the efficacy of OXC-101 (karonudib) in pre-clinical models of ovarian cancer – platinum resistant as well as platinum sensitive. The recently published findings demonstrate good efficacy of OXC-101 treatment in platinum sensitive as well as platinum resistant ovarian cancer cell lines. Furthermore, OXC-101 treatment increases survival in ovarian cancer-patient derived xenograft disease models. OXC-101 enhances the effects of carboplatin in the disease models, supporting its further development as a potential novel therapy for ovarian cancer. Oxcia has ongoing discussions to conduct investigator led clinical trial in ovarian cancer patients at the Mayo Clinic.
Read more in the article:Hurley et al., Mitotic MTH1 inhibitor karonudib kills epithelial ovarian cancer independent of platinum sensitivity, Exp Hematol Oncol. 2025 Jun 23;14(1):88. doi: 10.1186/s40164-025-00681-0. PMID: 40551177; PMCID: PMC12183885.
For more information contact:
Ulrika Warpman Berglund, CEO, Oxcia AB (publ)
Telephone: +46 (0) 73 270 9605
ulrika.warpmanberglund@oxcia.com
Briefly about Oxcia AB
Oxcia’s aim is to improve and extend lives by developing new innovative treatments based on our unique technology platform, O2-DDR. Oxcia AB is a pioneer in oxidative DNA damage and DNA Damage Response (DDR – the processes the body uses to repair the damage that occurs to DNA) with a focus on developing new safe and effective treatments for patients suffering from diseases caused by cancer or inflammation. Oxcia currently has two O2-DDR lead drug candidates, both with the potential to become first-in-class drugs. OXC-101 is in early clinical development as novel cancer therapy. OXC-201 is developed against idiopathic pulmonary fibrosis, and is in the preclinical phase. The portfolio also includes exploratory projects, e.g in psoriasis.
More information about Oxcia is available at www.oxcia.com